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Summary The TATA of two clones from the same murine methylcholanthrene-induced fibrosarcoma have
been investigated by immunizing syngeneic mice with irradiated cells of one or both clones and challenging
them 14 days later with viable cells. The tumour had been induced in a female backcross CBA mouse
heterozygous for the A and B alloenzymes of phosphoglycerate kinase-l (PGK-1). One clone expressed A and
the other B, and both A and B hosts were used in the experiments. Each clone was found to possess
strong TATA but there was no demonstrable cross reactivity. The clonal composition of tumours produced
by inoculating mice with a mixture of the two clones was profoundly altered by prior immunization with one
of them.
A second experiment was performed with 3 clones from another tumour; these expressed PGK-1 A, B and
AB respectively. Again, there was no evidence of immunological cross reactivity between the A and B clones,
but there was some cross reactivity between the A clone and AB clone. These results, coupled with previous
observations of changes in the clonal composition of pleoclonal murine fibrosarcomas in culture and on
transplantation, suggest that the antigenic specificity of these tumours is less stable than is commonly
supposed.
Some tumours, notably fibrosarcomas induced in
rodents with polycyclic hydrocarbon carcinogens,
possess antigens termed tumour associated
transplantation antigens (TATA) (See Woodruff,
1980 for review) which induce resistance to
transplants of the tumour in hosts syngeneic with
the one in which the tumour originated (the
autochthonous host). It has also been shown that
transplants of some tumours induce resistance in
the autochthonous host itself, although as Klein &
Oettgen (1969) have pointed out, "this does.not, in
the strict sense, answer the question of whether,
and to what extent, the primary host can mobilize a
rejection response against its own tumour cells as
they increase in number at their natural pace and at
the site of origin."
The TATA of chemically-induced murine fibro-
sarcomas are remarkably polymorphic. Moreover,
as Prehn & Main (1957) first reported, there is
often, though not invariably, no demonstrable cross
reactivity between the TATA of different sarcomas
induced with the same carcinogen, including
sarcomas induced at different sites in the same
mouse (Globerson & Feldman, 1964; Rosenau &
Morton, 1966). Differences in TATA specificity
between tumour sublines established by
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transplantation of tissue from opposite poles of the
same tumour have also been demonstrated (Prehn,
1970; Pimm et al., 1980). We now report two
instances in which a pair of clones from the same
primary tumour, chosen at random except for the
proviso that they bore different alloenzyme
markers, though strongly antigenic, showed no
evidence of cross reactivity. Moreover the clonal
composition of tumours produced by inoculating a
mixture of two clones from the same tumour was
radically altered by prior immunization with one of
them.
The tumours had been induced with methyl-
cholanthrene (MC) in female backcross CBA mice
(Pgk-la/PGK-lb, abbreviated to AB) heterozygous
for two forms (A and B) of the enzyme phospho-
glycerate kinase-1. In tissue culture the first tumour
(numbered W319 or DlI) expressed both A and B
alloenzymes in substantial amounts in all cultures
for several culture generations, A being the larger
component in some cultures and B in others. The
second tumour (numbered W324 or S1O) expressed
only the B alloenzyme in primary culture, but both
A and B in substantial amounts in all subsequent
cultures. Numerous clones expressing either A only
or B only were isolated from both tumours and
stored in liquid nitrogen; in addition, some clones
expressing both A and B were isolated from SlO,
and both components persisted on re-cloning and
also on re-recloning after passage in vivo.
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Materials and methods
Tumour and clones
The origin of the tumours and their alloenzyme
phenotypes, the method of preparing tumour cell
suspensions, and the techniques of tissue culture
and cloning have been described previously
(Woodruff et al., 1982a).
An A clone and a B clone were chosen at
random from each tumour. They were numbered as
follows:
Clone 6 (C6) expressing A, and Clone 12 (C12)
expressing B, from tumour Dl 1.
Clone 17 (Cl7) expressing A, clone 49 (C49)
expressing B, and clone 2 reclone 11 (C2RC11)
expressing A and B, from S10.
All clones were passaged once in irradiated
(4.7Gy) CBA mice, and then one or more times in
untreated CBA mice, before being used in the
experiments.
Mice
Female CBA/Ca mice expressing PGK-l B (Pgk-
lb/Pgk-lb, abbreviated to BB) were purchased from
Bantin and Kingman Ltd., Hull, England. Male
and female CBA backcross mice expressing PGK-1
A (Pgk-l/Y, abbreviated to AY; Pgk-la/Pgk-Ia,
abbreviated AA) were produced in the Department
of Zoology, University of Edinburgh, as described
previously. Histocompatibility between CBA/Ca
and the backcross mice has been demonstrated by
the survival of donor cells in both directions after
bone marrow infusion in high dosage (2.108 cells
over 5 days) to untreated recipients (Brecher et al.,
1982). Confirmation is provided by the absence of
graft-versus-host disease after transplantation of
marrow to irradiated recipients in doses of up to
1 x 107 cells.
Irradiation
Mice were irradiated in a 15 cm diam. circular
perspex container at a dose rate of approximately
0.37Gymin-1 with a Siemens Stabiliplan 2 X-ray
machine (250kv; focus target distance 62cm; filter
half value layer 3.3mm Cu). The dose was
measured at the centre of the field, using a
phantom and a Farmer Type 2570 dosemeter
corrected for temperature and barometric pressure;
the mean dose (4.7Gy) was 95% of this value and
the variation over the whole area of the container
was +5%.
Cell suspensions were irradiated in siliconized
glass bijoux bottles or, for small quantities,
Eppendorf polypropylene centrifuge tubes, with a
60Co source at a dose rate of - 2.8 Gymin-1.
TATA assays
Assays for TATA were performed routinely in BB
hosts but in some cases A hosts were also used.
"Immunized mice" were given a single s.c.
injection of irradiated (220Gy) cells (106 C6, 106
C12, or a mixture of 106 C6 and 106 C12) to one
hind limb on Day -14, and challenged with a s.c.
injection of non-irradiated viable cells (5 x 105 C6,
5 x 105 C12, or a mixture of 5 x 105 C6 and 5x 105
C12) to the opposite hind limb on Day 0. "Control
mice" received only an injection of viable cells in
similar dosage on Day 0.
The thickness of the two hind limbs was
measured thrice weekly with a caliper, and the
following indices were calculated on the first day on
which the mean increase in limb thickness in the
controls exceeded 5mm:
Mean increase in limb thickness in mice
immunized with cells of population i and
'R challenged with cell ofpopulation c
Mean increase in limb thickness in non-
immunized control mice challenged with
population c
'I =100 (1-'R)%
lR is termed the size ratio
cI is termed the effective immunogenicity of
population i against population c
When i and c denote the same population the
superscript and subscript are omitted.
This is a generalization of the method used
previously (Woodruff et al., 1982b) to express the
capacity of a tumour cell population to evoke
transplant immunity against itself.
Alloenzyme assays
To assess the proportion of each clone in tumours
which developed after challenge with a mixed
population, PGK-1 alloenzyme assays were
performed on samples derived from these tumours
and also, as controls, from tumours which
developed after single clone challenge. Since whole
tumour suspensions contain a proportion of normal
cells, assays were also performed on tissue cultures
and subcultures derived from them. In a few cases
whole tumour suspensions were also injected to
mice of one or other phenotype.
The techniques were, with minor modifications,
the same as those previously reported (Woodruff et
al., 1982a). In brief, tissue culture flasks (Falcon,
75cm2) were seeded with 107 viable cells and
incubated at 37°C in an atmosphere containing 5%
CO2. After 18h non-adherent cells were discarded,
and moderately adherent cells were harvested byTATA OF TUMOUR CLONES 7
brief exposure to trypsin (0.07%) and EDTA
(0.027%), and used to set up subcultures. This
procedure eliminates nearly all the leucocytes
(which are non-adherent) and macrophages (which
are strongly adherent) but not fibroblasts. Samples
from whole tumour suspensions and tissue cultures
were frozen and thawed in lytic buffer, and the
proportions of the two alloenzymes were
determined by gel electrophoresis, using a
modification of the linked enzyme assay developed
by Biucher et al. (1980), the production of NADPH
being visualized by the reduction of a tetrazolium
dye, thiazolyl blue, to its formazan derivative. In
the present experiments the gels were scanned with
an integrating densitometer instead of by eye as
previously.
Results
Tumour Dl]
The results are summarized in Tables I and II.
It will be seen that, as judged by the response of
immunized mice to challenge with viable tumour
Table I Clones from tumour DlI . Tests for TATA and cross reactivity by transplantation to normal and immunized mice
ofPGK-l phenotype B
% B component in
No. of Effective primary transplantb
mice Days to Tumour immuno-
Cells Cells No. of which tumour size ratioa genicitya Whole First Third
used to used to mice developed endpointa R I tumour generation generation
immunize challenge tested tumours (median) (mean) % suspension culture culture
Nil C6 10 10 11 13-46 trace-17 nil
C12 10 9 16 100 100
C6+C12 15 15 11 12 49c trace-54 nil-trace
C6 C6 7 2 0.07 93 16 13 nil
(PGK-1A) C12 8 8 15 1.03 0 100 100 100
C6+C12 5 4 16 0.17 83 100,100 100,100 100,100
100, 47 100, 42 100, 36
C12 C6 5 5 11 1.12 0 21-25 trace-17 nil-trace
(PGK-lB) C12 5 0 0 100
C6+C12 5 5 13 1.14 0 13-29 15-30 nil-trace
C6+C12 C6+C12 5 4 21 0.16 84
aDefined in text.
bIndividual values in line 6; elsewhere only the extremes are shown.
cFive of these whole tumour suspensions were re-transplanted to PGK-1 A mice.
these secondary transplants.
No B component was found in any of
Table II Clones from tumour DlI. Tests for TATA and cross reactivity by transplantation to normal and immunized
mice ofPGK-l phenotype A
% A component in
No. of Effective primary transplant
mice Days to Tumour immuno-
Cells Cells No. of which tumour size ratioa genicitya Whole First Third
used to used to mice developed endpoint' R I tumour generation generation
immunize challenge tested tumours (median) (mean) % suspension culture culture
Nil C12 4 4 24 31 11 0
C6+C12 4 4 12 100 100
C6 C6+C12 4 3 21 0.30 70 trace-33 nil-trace nil
(PGK-1A)
C12 C6+C12 4 4 14 0.75 25 100 100
(PGK-1B)
C6+C12 C6+C12 4 3 21 0.25 75 80-90 90-95 100
aDefined in text.8 M.F.A. WOODRUFF et al.
cells in the dosage used, immunization with either
clone conferred a high degree of protection against
challenge with the same cl6ne but no protection
against challenge with the other clone. It seems
clear, therefore, that each clone possesses strong
TATA, but there is no evidence that they have any
TATA in common.
The results of challenge with a mixture of the
two clones confirm these conclusions. In
interpreting the findings one must take into account
the probability that the sample tested contains non-
transformed host cells in sufficient number to affect
the results of the alloenzyme assay. Assays of
tumours developing after injection of cells of a
single clone to control (non-immunized) hosts (top
lines of Tables I and II) show that the host
component may be substantial in whole tumour
suspensions and still significant in first generation
cultures, but absent or detectable only in trace
amounts (up to 10%) in third generation cultures. It
seems likely that the amount of host component in
samples from tumours which develop after injection
of clonal mixtures is of the same order, and the
presence of only one component on retrans-
plantation of such tumours to mice of appropriate
phenotype (Table I, line 3) confirms this view. We
conclude therefore that, when a mixture of equal
numbers of C6 and C12 cells is transplanted to
immunized hosts, the C12 cells usually disappear
(Table I, line 3; Table II, line 2); in hosts pre-
immunized with C6 cells, however, the C12 cells,
and usually they alone, persist and multiply (Table
I, line 6; Table II, line 3).
Immunization with a mixture of both clones
slowed, but except in one mouse did not prevent,
tumour growth in response to challenge with a
mixture of equal numbers of viable C6 and C12
cells (Table I, line 10; Table II, line 5), and
eliminated the C12 (Table II, line 5), but not the C6
component. It seems therefore that the immunizing
effect of irradiated C6 cells is somewhat reduced
when they are mixed with irradiated C12 cells; an
alternative possibility, which seems less likely, is
that viable C6 cells are protected to some extent
when viable C12 cells are included in the challenge
inoculum.
Tumour SJO
The results are summarised in Table III. As with
the other tumour the clones tested are clearly
strongly immunogenic (top three lines of Table).
There is no evidence of cross reactivity between
C17 and C49 (Table III, lines 5 and 7) or between
C49 and C2RCl (Table III, lines 9 and 11). There
is, on the other hand, evidence of cross reactivity in
both directions between C17 and C2RCl (Table
III, lines 6 and 10), indicating that these clones
have some antigens in common.
Discussion
It seems clear that, with both the tumours studied,
a pair of clones chosen randomly, except for the
proviso that they were of different alloenzyme
Table Ill Clones from tumour S10. Tests for TATA and cross reactivity by
transplantation to normal and immunized mice ofPGK-l phenotype B
No. of
mice Days to Tumour immuno-
Cells Cells No. of which tumour size ratioa genicitya
used to used to mice developed endpointa R I
immunize challenge tested tunours (median) (mean) %
Nil C17 5 5 18
C49 5 5 27
C2RC11 5 5 13
C17 C17 5 0 0 100
(PGK-1A) C49 5 5 26 1.16 0
C2RC11 5 2 0.40 60
C49 C17 5 5 16 1.12 0
(PGK-1B) C49 5 0 0 100
C2RC11 5 0 0 100
C2RCl1 C17 5 1 0.16 84
(PGK-IAB) C49 5 0 0 100
C2RC1 5 0 0 100
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phenotype, and without prior knowledge of their
immunological properties, differ in respect of their
expression of TATA. The results are consistent with
the stronger conclusion that the pairs in question
have no TATA in common, though further
experiments, using a range of cell doses for both
immunization and challenge, would be needed to
prove this. This finding points to the need for
caution in interpreting experiments based on the
transplantation of tumour tissue or whole tumour
suspensions, because clones may be selected to an
extent which depends on their immunogenicity and
their susceptibility to immunological killing.
The cross reactivity between C17 and C2RC1 1 is
of interest. If, as we have already postulated
(Woodruff et al., 1982a), clones like C2 that express
both alloenzyme phenotypes have arisen from
hybrid cells, the simplest explanation is that C2 has
developed from a hybrid formed by the fusion of a
cell belonging to C17 with a cell expressing PGK-1
B but not belonging to C49. Further experiments
are planned to test this hypothesis.
Autochthonous pleoclonal tumours are also
exposed to selection pressures, and the extent to
which a particular clone is favoured will depend not
only on its intrinsic properties but also on extrinsic
factors which affect the host reaction, including
therapeutic procedures of various kinds.
It is widely accepted that the TATA of most
chemically induced tumours are distinctive and
stable characteristics of each individual tumour
(Baldwin et al., 1979). The claim of stability rests
mainly on the observation that, as a rule, a primary
tumour that is strongly, weakly or non-
immunogenic retains this property for many
generations when serially transplanted in the strain
of origin (Prehn, 1982), but important exceptions to
this rule have been reported. Globerson and
Feldman (1964), for example, found that highly
immunogenic benzopyrene-induced sarcomas
regularly lost their immunogenicity within three
transplant generations, and Prehn (1982) himself
observed that the immunogenicity of a tumour
sometimes appeared to rise or fall in successive
transplant generations "without any apparent
reason." There is less evidence concerning the
extent to which antigenic specificity remains
constant. Globerson & Feldman (1964) reported
that tumours that could no longer immunize
animals were still susceptible to the immune
response elicited by immunogenic grafts of earlier
transplant generations, but in only two instances
was the test graft more than one transplant
generation removed-from the immunizing graft.
The discovery that methylcholanthrene-induced
murine sarcomas are often pleoclonal (Reddy &
Fialkow, 1979; Woodruff et al., 1982a), and that
their clonal composition may change markedly on
transplantation or in tissue culture (Woodruff et al.,
1982a), coupled with our present findings, implies
however that antigenic specificity may also be
unstable, because changes in clonal composition
may result in corresponding changes in the TATA
expressed by the tumour. We see no compelling
reason to postulate that the antigens expressed by
individual clones may also change, but this
possibility cannot be excluded on the evidence
available.
Little is known about the factors which regulate
the clonal composition of tumours but our results
show that, with an immunogenic tumour, striking
changes may be produced by manipulation of the
host's immunological response. Our experiments
illustrate elimination of a particular clone but the
possibility of immunostimulation (Prehn, 1976,
1982) must also be considered.
Although nearly 30 years have elapsed since the
polymorphism of the TATA of chemically-induced
tumour was discovered (Baldwin, 1955; Prehn &
Main, 1957), the molecular basis for their diversity
is still unknown (Parmiani & Pierotti, 1983). One
suggestion, put forward by Lennox (1980), is that
the specificity of the TATA of chemically induced
murine sarcomas is carried on envelope glyco-
protein (gp7O) molecules of mouse leukaemia retro-
viruses (MuLV). There is good evidence that these
tumours may express MuLV antigens which are
detectable serologically, and it may well be true, as
Lennox has claimed, that MuLV is sufficiently
polymorphic to account for the great diversity of
their TATA; but comparison of the amino acid
composition of TATA isolated from an MC-
induced fibrosarcoma and gp7O from the Rauscher
strain of MuLV (Du Bois et al., 1982) does not
support Lennox's hypothesis.
It might be rewarding to use the methods of Du
Bois et al. (1982) to purify TATA from tumour
clones. It would also be of interest to raise
monoclonal antibodies to tumour clones by the
technique, already used with whole tumours
(Simrell & Klein, 1979; Lennox et al., 1981), in
which myeloma cells are fused with spleen cells
from tumour bearing animals, and to study
reactions between antibodies raised with one clone
and the cells of other clones from the same tumour.
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